%V 28
%P S27-S27
%D 2018
%O This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
%K Periodic Paralysis, Channelopathy, Hypokalaemic Periodic Paralysis, CMAP, Phase II, Drug repurposing study, Long exercise test, Neurophysiology, Outcome measure, Treatment
%J Neuromuscular Disorders
%A RS Scalco
%A J Morrow
%A A Manole
%A I Skorupinska
%A A Bellin
%A F Ricciardi
%A E Matthews
%A M Hanna
%A D Fialho
%T RCT of Bumetanide in Hypokalaemic Periodic Paralysis (HypoPP) using abductor digiti minimi compound muscle action potential (CMAP) as an objective outcome measure
%N S1
%C Neuromuscular Disorders
%L discovery10047475
%I Elsevier